Feb. 27 at 4:39 PM
$BEAT I use the 7/21 rule for screening rebounds. Besides a quick chart perusal, catalyst identification, SEC filing review, and short interest eval, it’s pretty helpful. In the case of BEAT, the seven day EMA is nearing the point of crossover. With that increased price target released yesterday and the very large likelihood that anyone with intelligence picks up their tech, you can expect big things from this stock. Besides
$FEED , it’s my favorite biotech right now.